Deferasirox的用法及用量

(Delasirox, Enrig) is very effective. It plays a good auxiliary role in patients with thalassemia or other rare anemias that require long-term blood transfusions that lead to iron accumulation (people who require long-term blood transfusions (blood transfusion volume up to 100 ml/kg) and whose serum ferritin exceeds 1000 μg/L). So, what is the usage and dosage of Deferasirox?

Starting dose:

The recommended starting daily dose of Deferasirox is 20 mg/kg. 

For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. 

For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. 

In patients who have already responded well to deferoxamine therapy, an initial dose of Enriga equivalent to half the deferoxamine dose may be considered. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days a week or equivalent, may start with 20 mg/kg if switched to Enriga.)

How to take:

Deferasirox should be taken once daily on an empty stomach, at least 30 minutes before a meal, preferably at the same time each day. Tablets should not be chewed or swallowed whole.  

Deferasirox (Deferasirox, Enrig) should not be taken with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. 

Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before taking. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Deferasirox (Deferasirox, Enrig) Dose Adjustments: Myelosuppression: Interrupt treatment; may restart once cause of cytopenias is determined; Contraindicated if platelet count <50,000/mm; Cutaneous Toxicity: Rash (serious): Interrupt treatment; may reintroduce at lower doses (with future dose escalations) and short-term oral corticosteroids. Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme): Stop and evaluate. Gastrointestinal: Discontinue treatment for suspected gastrointestinal ulceration or bleeding. Hearing loss or visual impairment: Consider dose reduction or treatment interruption.

The above is the dosage content of (Deferasirox, Enriga), I hope it can help you!